Real-world pharmacogenomics-guided antihypertensive treatment response in clinical practice underrepresented population: implications for precision prescribing and medication safety
Sep 2026· European Journal of Clinical Pharmacology· Vol 82· 0 citations· 29 references
Medicine
TL;DR
This retrospective cohort study analyzed 1,247 hypertensive patients treated at Kuwait Teaching Hospital (KTH), Peshawar, between January 2023 and August 2025 to evaluate associations between pharmacogenomics variants and antihypertensive therapy response using electronic health record (EHR) data from Khyber Pakhtunkhwa patients.
Background The advent of pharmacogenomics-guided antihypertensive therapy represents a paradigm shift in hypertension management. This study aimed to investigate the prevalence of relevant genetic variants among hypertensive patients in Hunan Province, China, and evaluate the efficacy of genotype-directed vs. clinicall...
Sha Wu, Wen-Wu Liu, Long Chen et al.· Frontiers in Cardiovascular...· 0 citations
Overall, pharmacogenomic-guided dose adjustment is a promising strategy to support safer and more precise pharmacotherapy, although broader implementation requires standardized guidelines, prospective validation, population-specific evidence, and integration into routine healthcare systems.
Zakiah Thahir, Rahmah Mustarin, Rahmadani Rahmadani et al.· Indonesian Journal of Pharma...· 0 citations
Objectives: Adverse drug reactions (ADRs) to antihypertensive medications contribute to poor medication adherence and treatment discontinuation. Pharmacogenomic approaches offer a potential means of identifying genetic variants that predict ADR risks, thereby supporting more tailored antihypertensive therapy and improv...
V. Dsouza, Jestina Rachel Kurian, Manuj Kalita et al.· Pharmaceuticals· 0 citations
Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies.
S. Garg, R. Kitchen, R. Gupta et al.· Diabetes, obesity and metabo...· 0 citations
A portion of population ADR burden could possibly have been prevented through PGx-guided therapy and a portion of population ADR burden could possibly have been prevented through PGx-guided therapy.
R. Torene, Ryley Uber, Tracy Brandt et al.· Genetics in Medicine· 0 citations
